Regadenoson是一種A2A腺苷受體激動劑是一種冠狀動脈血管擴(kuò)張劑。
適應(yīng)證：Lexiscan是一種藥理學(xué)應(yīng)激劑適用于在不能進(jìn)行適當(dāng)運(yùn)動負(fù)荷患者中放射性核素心肌灌注顯像(MPI)。
劑量和用法：Lexiscan推薦的劑量是5 mL (0.4 mg regadenoson)通過迅速靜脈注射；隨后立即用鹽水和放射性藥物沖洗。
禁忌證：有二級或三級AV阻滯，或竇房結(jié)功能失調(diào)患者不能給予Lexiscan除非患者 有功能良好的人工心臟起搏器
不良反應(yīng)：對Lexiscan最常見(發(fā)生率 ≥ 5%)不良反應(yīng)是呼吸困難、頭痛、面紅、胸部不適、眩暈、心絞痛、胸痛、和惡心。
藥物相互作用：甲基黃嘌吟類，如，咖啡因和茶堿，可能干擾Lexiscan的活性。 氨茶堿可能用于減輕嚴(yán)重和/或?qū)exiscan的持久不良反應(yīng)。
[1]MIYAMOTO MI,VERNOTICO SL,MAJMUNDAR H,et al.Pharmacologic stress myocardial perfusion imaging:a practicalapproach[J].J Nucl Cardiol,2007,14(2):250-255.
[2]PRESS NJ,GESSI S,BOREA PA,et al.Therapeutic potentialof adenosine receptor antagonists and agonists[J].Expert OpinTher Pat,2007,17(8):979-991.
[3]SPICUZZA L,DI MARIA G,POLOSA R.Adenosine in theairways:implications and applications[J].Eur J Pharmcol,2006,533(1-3):77-88.
[4]CERQUEIRA MD.Advances in pharmacologic agents in imaging:new A2A receptor agonists[J].Curr Cardiol Rep,2006,8(2):119-122.
[5]JAROUDI WA,ISKANDRIAN AE.Regadenoson:a new myo-cardial stress agent[J].J Am Coll Cardiol,2009,54(13):1123-1130.
[6]ZHAO G,LINKE A,XU X,et al.Comparative profile ofvasodilation by CVT-3146,a novel A2A receptor agonist,andadenosine in conscious dogs[J].J Pharmacol Exp Ther,2003,307(1):182-189.
[7]TROCHU JN,ZHAO G,POST H,et al.Selective A2A adeno-sine receptor agonist as a coronary vasodilator in conscious dogs:potential for use in myocardial perfusion imaging[J].J CardiovascPharmacol,2003,41(1):132-139.
[8]HAGE FG,HEO J,FRANKS B,et al.Differences in heart rateresponse to adenosine and regadenoson in patients with andwithout diabetes mellitus[J].Am Heart J,2009,157(4):771-776.
[9]GAEMPERLI O,SCHEPIS T,KOEPFLI P,et al.Interaction ofcaffeine with regadenoson-induced hyperemic myocardial bloodflow as measured by positron emission tomography:arandomized,double-blind,placebo-controlled crossover trial[J].JAm Coll Cardiol,2008,51(3):328-329.
[10]ZHAO G,MESSINA E,XU X,et al.Caffeine attenuates theduration of coronary vasodilation and changes in hemodynamicsinduced by regadenoson(CVT-3146),a novel adenosine A2Areceptor agonist[J].J Cardiovasc Pharmacol,2007,49(6):369-375.
[11]LIEU HD,SHRYOCK JC,von MERING GO,et al.Regadenoson,a selective A2A adenosine receptor agonist,causes dose-dependent increases in coronary blood flow velocity in humans[J].J Nucl Cardiol,2007,14(4):514-520.
[12]HENDEL RC,BATEMAN TM,CERQUEIRA MD,et al.Initialclinical experience with regadenoson,a novel selective A2Aagonist for pharmacologic stress single-photon emission computedtomography myocardial perfusion imaging[J].J Am Coll Cardiol,2005,46(11):2069-2075.
[13]CERQUEIRA MD,NGUYEN P,STAEHR P,et al.ADVANCE-MPI Trial Investigators.Effects of age,gender,obesity,anddiabetes on the efficacy and safety of the selective A2A agonistregadenoson versus adenosine in myocardial perfusion imaging:integrated ADVANCE-MPI trial results[J].JACC CardiovascImaging,2008,1(3):307-316.
[14]ISKANDRIAN AE,GARCIA EV,FABER T.Analysis of serialimages:a challenge and an opportunity[J].J Nucl Cardiol,2008,15(1):23-26.
[15]LEAKER BR,O’CONNOR B,HANSEL TT,et al.Safety ofregadenoson,an adenosine A2A receptor agonist for myocardialperfusion imaging,in mild asthma and moderate asthmapatients:a randomized,double-blind,placebo-controlled trial[J].J Nucl Cardiol,2008,15(3):329-336.
[16]THOMAS GS,TAMMELIN BR,SCHIFFMAN GL,et al.Safetyof regadenoson,a selective adenosine A2A agonist,in patientswith chronic obstructive pulmonary disease:a randomized,double-blind,placebo-controlled trial(RegCOPD trial)[J].JNucl Cardiol,2008,15(3):319-328.
[17]Palle, V.P., et al.: J. A. Drug Dev. Res., 50, 64 (2000)。
[18]Gordi, T., et al.: J. Clin. Pharmacol., 47, 825 (2000)
[19]Zhao, G., et al.: J. Cardiovas. Pharmacol., 52, 467 (2000)
[20]Botvinick, E., et al.: J. Nuc. Med. Technol., 37, 14 (2000)
